We are live on ! Find out more
BJCM

Blue Jay Capital Management Portfolio holdings

AUM $147M
1-Year Est. Return 64.18%
This Fund
S&P 500
This Quarter Est. Return
+9.48%
1 Year Est. Return
+64.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$297M
AUM Growth
+$42M
Cap. Flow
+$28.5M
Cap. Flow %
9.59%
Top 10 Hldgs %
53.44%
Holding
31
New
13
Increased
3
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$19.1M
2
ENDP
Endo International plc
ENDP
+$15.5M
3
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$13.4M
4
HOLX
Hologic
HOLX
+$12.7M
5
IPXL
Impax Laboratories, Inc.
IPXL
+$11.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$16M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$14.1M
4
NUVA
NuVasive, Inc.
NUVA
+$13.7M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$12.9M

Sector Composition

Rank Sector Weight
1 Healthcare 82.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
1
Intuitive Surgical
ISRG
$121B
$20.2M 6.81%
333,000
+63,000
+23% +$3.54M
EW icon
2
Edwards Lifesciences
EW
$47.6B
$19.9M 6.72%
757,500
-146,604
-16% -$3.81M
SHPG
3
DELISTED
Shire pic
SHPG
$18.9M 6.36%
+92,030
New +$19.1M
BIIB icon
4
Biogen
BIIB
$29.9B
$17.8M 6.01%
58,161
+15,661
+37% +$4.5M
ENDP
5
DELISTED
Endo International plc
ENDP
$15.6M 5.26%
+255,080
New +$15.5M
BXLT
6
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$15M 5.07%
+385,000
New +$13.4M
CERN
7
DELISTED
Cerner Corp
CERN
$13M 4.39%
216,339
+36,339
+20% +$2.24M
NVRO
8
DELISTED
NEVRO CORP.
NVRO
$12.8M 4.32%
+190,000
New +$10.2M
IPXL
9
DELISTED
Impax Laboratories, Inc.
IPXL
$12.6M 4.25%
+295,000
New +$11.8M
HOLX
10
DELISTED
Hologic
HOLX
$12.6M 4.25%
+325,747
New +$12.7M
DGX icon
11
Quest Diagnostics
DGX
$25.1B
$12.5M 4.2%
+175,160
New +$11.8M
COO icon
12
Cooper Companies
COO
$13.7B
$12.1M 4.07%
360,000
-120,000
-25% -$4.29M
A icon
13
Agilent Technologies
A
$39.1B
$11.9M 4.02%
+285,000
New +$11M
BMY icon
14
Bristol-Myers Squibb
BMY
$127B
$11.3M 3.81%
+164,518
New +$10.9M
NBIX icon
15
Neurocrine Biosciences
NBIX
$17.7B
$11.3M 3.81%
+200,060
New +$10.2M
WMGI
16
DELISTED
Wright Medical Group Inc
WMGI
$10.9M 3.67%
450,000
-115,000
-20% -$2.49M
CPHD
17
DELISTED
Cepheid Inc
CPHD
$10.6M 3.57%
290,000
-18,909
-6% -$672K
VRTX icon
18
Vertex Pharmaceuticals
VRTX
$121B
$10.1M 3.39%
80,020
-58,118
-42% -$7.02M
QGENF
19
DELISTED
QIAGEN NV
QGENF
$9.95M 3.36%
360,000
-65,000
-15% -$1.8M
ASRT
20
DELISTED
Assertio
ASRT
$9.7M 3.27%
+8,917
New +$10M
PRGO icon
21
Perrigo
PRGO
$1.4B
$9.49M 3.2%
65,600
-49,400
-43% -$7.6M
STJ
22
DELISTED
St Jude Medical
STJ
$9.42M 3.18%
+152,500
New +$9.62M
MASI
23
DELISTED
Masimo
MASI
$8.93M 3.01%
+215,000
New +$8.78M
BKD icon
24
Brookdale Senior Living
BKD
$3.62B
– –
-560,220
Closed -$12.9M
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-139,164
Closed -$14.7M
1
2

Similar funds

BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
RJA
Robshaw & Julian Associates Williamsville, New York $140M AUM 13.69% 1-Year Est. Return
RP
Ridgegate Proprietary Sydney, Australia $154M AUM 25.47% 1-Year Est. Return
ACPVT
ABS Capital Partners V Trust Baltimore, Maryland $123M AUM
SFA
Staton Financial Advisors Charlotte, North Carolina $118M AUM 11.07% 1-Year Est. Return
KL
Kinsight LLC Birmingham, Alabama $176M AUM 17.21% 1-Year Est. Return
KFS
Kissinger Financial Services Hunt Valley, Maryland $100M AUM 6.22% 1-Year Est. Return
FHC
First Houston Capital Houston, Texas $100M AUM 23.45% 1-Year Est. Return

Blue Jay Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Blue Jay Capital Management held 31 positions worth $297M, up 17% from $255M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Blue Jay Capital Management deployed $28.5M of net new capital in Q4 2015, opening 13 new positions and adding to 3 existing holdings. Its largest new stake was Shire pic: 92,030 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Perrigo, an estimated $7.6M trimmed.

  • Blue Jay Capital Management's largest Q4 2015 buy was Shire pic: 92,030 shares worth $18.9M.
  • Blue Jay Capital Management added most to Biogen in Q4 2015, an estimated $4.5M increase.
  • Blue Jay Capital Management's biggest Q4 2015 reduction was Perrigo, cutting an estimated $7.6M.
  • Blue Jay Capital Management fully exited Incyte in Q4 2015, selling an estimated $16M.
  • Blue Jay Capital Management's ten largest holdings make up 53% of its $297M portfolio in Q4 2015.
  • Blue Jay Capital Management opened 13 new positions and closed 8 in Q4 2015.
  • Blue Jay Capital Management's portfolio value rose 17% quarter-over-quarter to $297M.

Based on Blue Jay Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.